ALPN-202 – NEON-2 (Alpine Immune Sciences)
Description: An open-Label Study of ALPN-202 Combined With PD-1 Inhibition In Subjects With Advanced Malignancies (NEON-2)
Mechanism of Action: Inhibits PDL1 and CTLA4, engages CD28 co-stimulator in combination with Pembrolizumab.
Target Patient Population:. All solid tumors
Study Design: Study drug is administered IV every 1 or 3 weeks